Asimov

Asimov was awarded a contract through DARPA’s ASKE opportunity to develop a physics-based AI design engine for biology. The initiative aims to improve the reliability of programming complex cellular behaviors.

Asimov builds tools to program living cells and integrates mammalian synthetic biology with computer-aided design to advance therapeutic applications.

GitHubRepository owner

Asimov partners with Kaigene on cell line development for a multispecific antibody targeting autoimmune disease. The partnership spans vector design and synthesis through delivery of a high-titer research cell bank. The campaign uses Asimov’s CHO Edge System to support an antibody that selectively degrades pathogenic antibodies in autoimmune disease.

Aug 2026 · GlobeNewswireNews article

Kyungdong Pharmaceutical and Asimov complete a cell line development campaign for a biosimilar antibody candidate using Asimov’s CHO Edge System. Their collaboration delivers a high-performing production cell line intended to support both process development and large-scale manufacturing of the candidate.

Aug 2026 · GlobeNewswireNews article

Asimov joins the federal Genesis Mission to build therapeutic protein production and characterization capabilities at Boston University's node in the National Science Foundation's Programmable Cloud Laboratory test bed. The company plans to feed large-scale experimental data into models that predict manufacturability from protein sequence through a lab-in-the-loop cycle.

Jul 2026 · GlobeNewswireNews article